





# Innovation and Access in the European Policy

**Sophie Bloemen**

Health Action International

**16 December 2010**

Health Action International (HAI) is an independent, global network, working to increase access to essential medicines and improve their rational use through research excellence and evidence-based advocacy.



# Innovation and Access: You need both

- Access is an inherent problem of the current model as it depends on exclusive rights.
- There will always be exclusion of people who could benefit from medicines but have little resources.
- There is a lack of innovation where there is no profitable market

Health Action International (HAI) is an independent, global network, working to increase access to essential medicines and improve their rational use through research excellence and evidence-based advocacy.

# EU IP Policy

- Intellectual Property protection seen as core to knowledge economy & competitiveness
- Global Europe Strategy Paper > IP indicated as one of priorities.
- Free Trade Agreements (EPAs, Association Agreements)
- Bilateral pressure, multilateral fora; WHO, WTO, WIPO
- Enforcement agenda (ACTA, Internal EU regulation having effect on transit, IMPACT, etc)



# Something Else: Towards new models that ensure Access

- Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property. WHA 2008 Resolution 61.21
- Communication & Council Conclusions on Global Health
  - Exploration of new models of innovation that dissociate the cost of r&d and the price of medicines.
- Innovation Union Communication. Flagship 2020

Health Action International (HAI) is an independent, global network, working to increase access to essential medicines and improve their rational use through research excellence and evidence-based advocacy.



*A, working towards a **global framework for research and development that addresses the priority health needs of developing countries and prioritises pertinent research actions to tackle global health challenges in accordance with the WHO Global Research Strategy.***

- *c. **exploring models that dissociate the cost of Research and Development and the prices of medicines in relation to the GSPOA, including the opportunities for EU technology transfer to developing countries.***
- *d. ensuring that **EU public investments in health research secure access to the knowledge and tools generated as a global public good and help generate socially essential medical products at affordable prices, to be used through rational use.***



# Conference EP 18<sup>th</sup> November European Parliament

## **CAN WE AFFORD THE CURRENT MODEL OF INNOVATION > TOWARDS NEW MODELS.**

**BY:**

- European Parliament working group on Innovation and access.
  - Health Action International Europe
  - Oxfam
  - Trans Atlantic Consumer Dialogue
  - Knowledge Ecology International

# MAIN POINTS

- Current model has perverse incentives and does not provide for needs oriented innovation accessible for all.
- There is a need to explore and support both push and pull mechanisms for needs driven R&D that dissociate the cost of research and development and the price of a medical product



# New models that delink

- Open / Equitable licensing publicly funded research
- Product Development Partnerships -DNDI
- Unitaid Patent Pool
- Prizes for Innovation



# What can the EU Do?

- Ensure access to publicly funded research: Work towards making equitable/ open licensing in FP8
- Make sustainable funding more accessible for Product Development Partnerships.
- Explore new models of innovation through pilots and feasibility studies.
  - Including innovation inducement prizes that will reward health impact.
- Take note of the HIV/AIDS treatment bomb > second line treatment will be unaffordable for the GFTAM. Look into proposals that look to avoid this catastrophe.



# What can the EU do?

## Policy:

- Allow for and support the exploration truly innovative models that will structurally change the model of R&D on a global level.

Including WHO Expert Working Group on Alternative Financing for R&D explores

- Stop locking in the old model through over zealous Intellectual Property Protection that only benefits a few.



# Thank you

[sophie@haieurope.org](mailto:sophie@haieurope.org)

**Health Action International (HAI) is an independent, global network, working to increase access to essential medicines and improve their rational use through research excellence and evidence-based advocacy.**

**This paper was produced for a meeting organized by Health & Consumers DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumers DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.**